• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Declines to Disqualify Minneapolis Investigators and IRB from Running Trials

FDA Declines to Disqualify Minneapolis Investigators and IRB from Running Trials

May 9, 2022

The FDA has turned down a citizen petition seeking that the investigators and the institutional review board (IRB) at Minneapolis, Minn.-based Hennepin County Medical Center (HCMC) be barred from conducting clinical trials.

The petition, filed by Public Citizen in November, asked the FDA to disqualify two principal investigators (PIs) at HCMC, Jon Cole and Lauren Klein, as well as their co-investigators, for running multiple trials of investigational drugs without filing or possessing investigational new drug applications (IND). The center’s IRB was also in the crosshairs of the advocacy group, which argued that the board should be disqualified based on noncompliance (CenterWatch Weekly, Nov. 22, 2021).

Although the PIs contended that they did not need to get IND approvals for the trials in question because the trials involved noninvestigational drugs, the agency did not agree, issuing a pair of warning letters. In addition, the FDA sent a Form 483 to the medical center’s IRB, citing it for approving waivers of consent for the trials and approving research “in a situation where some or all of the subjects were likely to be vulnerable to coercion or undue influence” without ensuring safeguards were in place.

The agency appears to believe that the warning letters issued to the PIs in May 2021 and the Form 483 issued to the IRB in August 2018 are sufficient enforcement actions for now, though it noted it plans “to continue to consider all the options available to the agency as we determine whether to pursue additional compliance actions.”

Read the FDA’s final response to the citizen petition here: https://bit.ly/3yggyeO.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing